Hinokitiol Prevents Diabetic Acute Kidney Injury by Mitigating ER Stress
Cell Biology International · 2025-06 · 49 (6) · 645-658
DOI: 10.1002/cbin.70008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biology International, online erschienen am 27.02.2025. Verfasst von Tahib Habshi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Pilani, Rajasthan, India. Hauptthemen laut MEDLINE: Tropolone, Endoplasmic Reticulum Stress, Acute Kidney Injury, Monoterpenes. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Acute kidney injury (AKI) in diabetic conditions often advances to chronic kidney disease (CKD), exacerbated by ischemia–reperfusion injury (IRI) through pathomechanisms such as endoplasmic reticulum (ER) stress and inflammation. Currently, available treatment options for diabetic AKI are not uniformly effective, highlighting the need for novel interventions. This study aimed to examine the renoprotective effects of hinokitiol, a natural tropolone compound, against diabetic AKI with its capability to decrease ER stress and inflammation, along with apoptosis. This study involved NRK‐52E cells grown in‐vitro under high‐glucose conditions subjected to 10 mM sodium azide to elicit hypoxia/reperfusion injury (HRI). The expression of key ER stress markers like binding immunoglobulin binding protein (BiP), R/PKR‐like ER kinase (PERK), and eukaryotic initiation factor‐2 (eIF2α) as well as inflammatory proteins was markedly diminished by hinokitiol pretreatment (50 μM). Hinokitiol further reduced apoptosis in the NRK‐52E cells. Similarly, in the in‐vivo study, male Wistar rats with STZ‐induced Type 1 diabetes (55 mg/kg, i.p .) were treated with hinokitiol 50 and 100 mg/kg/day i.p . for 5 days, followed by AKI induction via bilateral IRI. Hinokitiol pretreatment significantly reduced the elevated plasma blood urea nitrogen (BUN), creatinine, and urinary kidney injury molecule‐1 (KIM‐1) levels and tubular damage in diabetic AKI rats. Hinokitiol also reduced the respective ER stress protein expressions in diabetic AKI rats, as demonstrated by immunohistochemical analysis and immunoblotting. These findings suggest that hinokitiol alleviates diabetic AKI by modulating the PERK/CHOP/NF‐κB axis, highlighting the likeliness of hinokitiol as a viable therapeutic technique for alleviating diabetic AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Pilani, Rajasthan, India.
ORCID-Profile: Tahib Habshi, Hrushikesh Kulkarni, Neha Dagar, Vishwadeep Shelke
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Habshi, T., Kulkarni, H., Dagar, N., Shelke, V., & Gaikwad, A. B. (2025). Hinokitiol Prevents Diabetic Acute Kidney Injury by Mitigating ER Stress. Cell Biology International, 49(6), 645-658. https://doi.org/10.1002/cbin.70008
Vancouver
Habshi T, Kulkarni H, Dagar N, Shelke V, Gaikwad AB. Hinokitiol Prevents Diabetic Acute Kidney Injury by Mitigating ER Stress. Cell Biology International. 2025;49(6):645-658. doi:10.1002/cbin.70008
BibTeX
@article{Habshi2025,
author = {Habshi, Tahib and Kulkarni, Hrushikesh and Dagar, Neha and Shelke, Vishwadeep and Gaikwad, Anil Bhanudas},
title = {Hinokitiol Prevents Diabetic Acute Kidney Injury by Mitigating ER Stress},
journal = {Cell Biology International},
year = {2025},
volume = {49},
number = {6},
pages = {645--658},
doi = {10.1002/cbin.70008}
}
EUVIMED